Global Single Nucleotide Polymorphism Snp Genotyping Market Drivers 2024, Forecast To 2033
8 Mar, 2024
The SNP genotyping market experienced exponential growth, reaching $8.48 billion in 2023 and projected to hit $10.24 billion in 2024, boasting a 20.7% CAGR. This surge stems from heightened genomics research, increased genetic disorder prevalence, personalized medicine expansion, and pharmaceutical industry growth. Anticipated rapid growth foresees the market reaching $20.6 billion by 2028, with a 19.1% CAGR, driven by disease research applications, precision medicine demand, biobanking initiatives, genetic testing surge, and agricultural adoption. Emerging trends include NGS usage, pharmacogenomics demand, direct-to-consumer testing, and automation focus.
Global Single Nucleotide Polymorphism SNP Genotyping Market Key Driver
The single nucleotide polymorphism (SNP) genotyping market is projected to grow as chronic conditions become more prevalent. By 2050, the number of people worldwide with chronic diseases is expected to double, driving demand for SNP genotyping systems to identify genetic predispositions, as forecasted by the National Center for Biotechnology Information (NCBI).
Get A Free Sample Of The Global Single Nucleotide Polymorphism SNP Genotyping Market ReportGlobal Single Nucleotide Polymorphism SNP Genotyping Market Segments
The single nucleotide polymorphism (snp) genotyping market covered in this report is segmented –
1) Product:Consumables, Instruments, services
2) Technology:TaqMan SNP Genotyping, Mass Array SNP Genotyping, SNP Gene Chip Arrays, Other Technologies
3) Application:Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals And Pharmacogenomics, Agricultural Biotechnology, Other Applications
By Geography: The countries covered in the single nucleotide polymorphism (snp) genotyping market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the single nucleotide polymorphism (SNP) genotyping market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single nucleotide polymorphism (snp) genotyping market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Single Nucleotide Polymorphism SNP Genotyping Industry Players
Thermo Fischer Scientific Inc.; Danaher Corporation; Roche Diagnostics Corporation; GE HealthCare Technologies Inc.; Eurofins Genomics LLC; Beckman Coulter Inc.; Bio-Rad Laboratories Inc.; Qiagen N.V.; Sigma-Aldrich Corporation; Agilent Technologies Inc.; PerkinElmer Inc.; Illumina Inc.; Promega Corporation; GenScript Biotech Corporation; Integrated DNA Technologies Inc.; LGC Ltd.; Sequenom Inc.; Fluidigm Corporation; Agendia Inc.; Nugen Technologies Inc.; BioChain Institute Inc.; Standard BioTools Inc.; Oxford Gene Technology; Affymetrix Inc.; PREMIER Biosoft International Inc.; GenoLogics; Rubicon Genomics Inc.; Xcelris Genomics; Douglas Scientific LLC; Golden Helix Inc.
Get The Full Global Single Nucleotide Polymorphism SNP Genotyping Market Report
Single Nucleotide Polymorphism SNP Genotyping Market Overview
Single nucleotide polymorphism (SNP) genotyping refers to a procedure that locates and describes genetic variants at the level of specific DNA nucleotides. It identifies individual SNPs, which are single-base changes in DNA sequences, and it is essential for understanding the genetic variations linked to diseases, traits, and population studies.